{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:41:54Z","timestamp":1794534114044,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"8058","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The membrane (M) protein of betacoronaviruses is well conserved and has a key role in viral assembly\n                    <jats:sup>1,2<\/jats:sup>\n                    . Here we describe the identification of JNJ-9676, a small-molecule inhibitor targeting the coronavirus M protein. JNJ-9676 demonstrates in vitro nanomolar antiviral activity against SARS-CoV-2, SARS-CoV and sarbecovirus strains from bat and pangolin zoonotic origin. Using cryogenic electron microscopy\u00a0(cryo-EM), we determined a binding pocket of JNJ-9676 formed by the transmembrane domains of the M protein dimer. Compound binding stabilized the M protein dimer in an altered conformational state between its long and short forms, preventing the release of infectious virus. In a pre-exposure Syrian golden hamster model, JNJ-9676 (25\u2009mg per kg twice per day) showed excellent efficacy, illustrated by a significant reduction in viral load and infectious virus in the lung by 3.5 and 4 log\n                    <jats:sub>10<\/jats:sub>\n                    -transformed RNA copies and 50% tissue culture infective dose (TCID\n                    <jats:sub>50<\/jats:sub>\n                    ) per mg lung, respectively. Histopathology scores at this dose were reduced to the baseline. In a post-exposure hamster model, JNJ-9676 was efficacious at 75\u2009mg per kg twice per day even when added at 48\u2009h after infection, when peak viral loads were observed. The M protein is an attractive antiviral target to block coronavirus replication, and JNJ-9676 represents an interesting chemical series towards identifying clinical candidates addressing the current and future coronavirus pandemics.\n                  <\/jats:p>","DOI":"10.1038\/s41586-025-08651-6","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T14:17:19Z","timestamp":1742998639000},"page":"506-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein"],"prefix":"10.1038","volume":"640","author":[{"given":"Ellen","family":"Van Damme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravien","family":"Abeywickrema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexiong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8657-6841","authenticated-orcid":false,"given":"Sofie","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8252-6107","authenticated-orcid":false,"given":"Mandeep Kaur","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1707-0174","authenticated-orcid":false,"given":"Jordi","family":"Doijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Piassek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Marsili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-7312","authenticated-orcid":false,"given":"Rana","family":"Abdelnabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5424-1377","authenticated-orcid":false,"given":"Michiel","family":"Van Gool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5900-4813","authenticated-orcid":false,"given":"Nick","family":"Van den Broeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"De Pauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Diels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Temmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Scobey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Mattocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4760-4923","authenticated-orcid":false,"given":"Alexandra","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-6028","authenticated-orcid":false,"given":"Dirk","family":"Jochmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-6558","authenticated-orcid":false,"given":"Steven","family":"De Jonghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7537-1688","authenticated-orcid":false,"given":"Pieter","family":"Leyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-623X","authenticated-orcid":false,"given":"Winston","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra","family":"Diosa Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Zwaagstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk A.","family":"Leijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi L. M.","family":"De Gruyter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Buyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas","family":"Van Den Heede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-3943","authenticated-orcid":false,"given":"Frank","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Van den Eynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Raeymaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-7149","authenticated-orcid":false,"given":"Amanda","family":"Del Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-7514","authenticated-orcid":false,"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-8701","authenticated-orcid":false,"given":"Ralph S.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-749X","authenticated-orcid":false,"given":"Frank J. M.","family":"van Kuppeveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3297-2309","authenticated-orcid":false,"given":"Eric J.","family":"Snijder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J.","family":"van Hemert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Monshouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7588-2939","authenticated-orcid":false,"given":"Sujata","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-4039","authenticated-orcid":false,"given":"Ruxandra","family":"Draghia-Akli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5542-4568","authenticated-orcid":false,"given":"Anil","family":"Koul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4151-4588","authenticated-orcid":false,"given":"Marnix","family":"Van Loock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"8651_CR1","doi-asserted-by":"crossref","first-page":"11318","DOI":"10.1128\/JVI.01052-08","volume":"82","author":"YL Siu","year":"2008","unstructured":"Siu, Y. L. et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J. Virol. 82, 11318\u201311330 (2008).","journal-title":"J. Virol."},{"key":"8651_CR2","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Structure of SARS-CoV-2 membrane protein essential for virus assembly. Nat. Commun. 13, 4399 (2022).","journal-title":"Nat. Commun."},{"key":"8651_CR3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019kovski","year":"2021","unstructured":"V\u2019kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155\u2013170 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"8651_CR4","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/jcm9041225","volume":"9","author":"YA Helmy","year":"2020","unstructured":"Helmy, Y. A. et al. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J. Clin. Med. 9, 1225 (2020).","journal-title":"J. Clin. Med."},{"key":"8651_CR5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/diseases4030026","volume":"4","author":"YX Lim","year":"2016","unstructured":"Lim, Y. X., Ng, Y. L., Tam, J. P. & Liu, D. X. Human coronaviruses: a review of virus-host interactions. Diseases 4, 26 (2016).","journal-title":"Diseases"},{"key":"8651_CR6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-022-04788-w","volume":"607","author":"CJ Carlson","year":"2022","unstructured":"Carlson, C. J. et al. Climate change increases cross-species viral transmission risk. Nature 607, 555\u2013562 (2022).","journal-title":"Nature"},{"key":"8651_CR7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrmicro.2017.45","volume":"15","author":"RK Plowright","year":"2017","unstructured":"Plowright, R. K. et al. Pathways to zoonotic spillover. Nat. Rev. Microbiol. 15, 502\u2013510 (2017).","journal-title":"Nat. Rev. Microbiol."},{"key":"8651_CR8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/challe13020041","volume":"13","author":"YA Tajudeen","year":"2022","unstructured":"Tajudeen, Y. A., Oladunjoye, I. O., Bajinka, O. & Oladipo, H. J. Zoonotic spillover in an era of rapid deforestation of tropical areas and unprecedented wildlife trafficking: into the wild. Challenges 13, 41 (2022).","journal-title":"Challenges"},{"key":"8651_CR9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.prrv.2004.07.009","volume":"5","author":"JD Cherry","year":"2004","unstructured":"Cherry, J. D. The chronology of the 2002\u20132003 SARS mini pandemic. Paediatr. Respir. Rev. 5, 262\u2013269 (2004).","journal-title":"Paediatr. Respir. Rev."},{"key":"8651_CR10","unstructured":"Lee, J. W. & McKibbin, W. J. Estimating the Global Economic Costs of SARS (National Academies Press, 2004)."},{"key":"8651_CR11","unstructured":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (WHO, 2023); www.who.int\/health-topics\/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1."},{"key":"8651_CR12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"8651_CR13","unstructured":"WHO Coronavirus (COVID-19) Dashboard (WHO, 2023); covid19.who.int\/."},{"key":"8651_CR14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1126\/science.adi6511","volume":"380","author":"K Kupferschmidt","year":"2023","unstructured":"Kupferschmidt, K. & Wadman, M. Ending COVID-19 states of emergency sparks debate. Science 380, 566\u2013567 (2023).","journal-title":"Science"},{"key":"8651_CR15","first-page":"162","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162\u2013177 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"8651_CR16","unstructured":"A Strong Pandemic Defence System Could Reduce the Chance of Another COVID Like Pandemic in the Next Ten years from 27.5% to 8% (Airfinity, 2023); www.airfinity.com\/articles\/a-strong-pandemic-defence-system-could-reduce-the-chance-of-another-covid."},{"key":"8651_CR17","unstructured":"Veklury (EMA, 2023); www.ema.europa.eu\/en\/medicines\/human\/EPAR\/veklury."},{"key":"8651_CR18","unstructured":"Know Your Treatment Options for COVID-19 (FDA, 2023); www.fda.gov\/consumers\/consumer-updates\/know-your-treatment-options-covid-19."},{"key":"8651_CR19","unstructured":"Fact Sheet for Healthcare Providers: Emergency Use Authorization for Lagevrio\u2122 (Molnupiravir) Capsules (FDA, 2023); www.fda.gov\/media\/155054\/download."},{"key":"8651_CR20","unstructured":"Paxlovid (EMA, 2023); www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid."},{"key":"8651_CR21","unstructured":"Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid, An Investigational Oral Antiviral for COVID-19 (Shionogi, 2023); www.shionogi.com\/global\/en\/news\/2023\/04\/20230404.html."},{"key":"8651_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29104-y","volume":"13","author":"S Gandhi","year":"2022","unstructured":"Gandhi, S. et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat. Commun. 13, 1547 (2022).","journal-title":"Nat. Commun."},{"key":"8651_CR23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/cid\/ciac769","volume":"76","author":"JI Hogan","year":"2023","unstructured":"Hogan, J. I. et al. Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019. Clin. Infect. Dis. 76, 342\u2013345 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"8651_CR24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"8651_CR25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459\u2013468 (2020).","journal-title":"Nature"},{"key":"8651_CR26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","volume":"27","author":"A Wu","year":"2020","unstructured":"Wu, A. et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27, 325\u2013328 (2020).","journal-title":"Cell Host Microbe"},{"key":"8651_CR27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","volume":"7","author":"W Yan","year":"2022","unstructured":"Yan, W., Zheng, Y., Zeng, X., He, B. & Cheng, W. Structural biology of SARS-CoV-2: open the door for novel therapies. Signal Transduct. Target. Ther. 7, 26 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"8651_CR28","unstructured":"Hogue, B. G. & Machamer, C. E. in Nidoviruses (eds Perlman, S. et al.) 179\u2013200 (ASM, 2007)."},{"key":"8651_CR29","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81702","volume":"11","author":"KA Dolan","year":"2022","unstructured":"Dolan, K. A. et al. Structure of SARS-CoV-2 M protein in lipid nanodiscs. eLife 11, e81702 (2022).","journal-title":"eLife"},{"key":"8651_CR30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jsb.2010.11.021","volume":"174","author":"BW Neuman","year":"2011","unstructured":"Neuman, B. W. et al. A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol. 174, 11\u201322 (2011).","journal-title":"J. Struct. Biol."},{"key":"8651_CR31","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3390\/ijms22031308","volume":"22","author":"NA Wong","year":"2021","unstructured":"Wong, N. A. & Saier, M. H. Jr The SARS-coronavirus infection cycle: a survey of viral membrane proteins, their functional interactions and pathogenesis. Int. J. Mol. Sci. 22, 1308 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"8651_CR32","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1002\/jmv.27683","volume":"94","author":"W Chiu","year":"2022","unstructured":"Chiu, W. et al. Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures. J. Med. Virol. 94, 3101\u20133111 (2022).","journal-title":"J. Med. Virol."},{"key":"8651_CR33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1099\/jgv.0.001453","volume":"101","author":"NS Ogando","year":"2020","unstructured":"Ogando, N. S. et al. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. J. Gen. Virol. 101, 925\u2013940 (2020).","journal-title":"J. Gen. Virol."},{"key":"8651_CR34","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00018-020-03745-y","volume":"78","author":"S Eymieux","year":"2021","unstructured":"Eymieux, S. et al. Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release. Cell. Mol. Life Sci. 78, 3565\u20133576 (2021).","journal-title":"Cell. Mol. Life Sci."},{"key":"8651_CR35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/v15020428","volume":"15","author":"M Castellan","year":"2023","unstructured":"Castellan, M. et al. Host response of Syrian hamster to SARS-CoV-2 infection including differences with humans and between sexes. Viruses 15, 428 (2023).","journal-title":"Viruses"},{"key":"8651_CR36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103595","volume":"72","author":"R Abdelnabi","year":"2021","unstructured":"Abdelnabi, R. et al. The combined treatment of molnupiravir and favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine 72, 103595 (2021).","journal-title":"EBioMedicine"},{"key":"8651_CR37","doi-asserted-by":"crossref","first-page":"eabq3059","DOI":"10.1126\/scitranslmed.abq3059","volume":"14","author":"JJ Frere","year":"2022","unstructured":"Frere, J. J. et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci. Transl. Med. 14, eabq3059 (2022).","journal-title":"Sci. Transl. Med."},{"key":"8651_CR38","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"8651_CR39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/vaccines10040591","volume":"10","author":"BAS Machado","year":"2022","unstructured":"Machado, B. A. S. et al. The importance of vaccination in the context of the COVID-19 pandemic: a brief update regarding the use of vaccines. Vaccines (Basel) 10, 591 (2022).","journal-title":"Vaccines (Basel)"},{"key":"8651_CR40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2208822","volume":"388","author":"Z Cao","year":"2023","unstructured":"Cao, Z. et al. VV116 versus nirmatrelvir-ritonavir for oral treatment of COVID-19. N. Engl. J. Med. 388, 406\u2013417 (2023).","journal-title":"N. Engl. J. Med."},{"key":"8651_CR41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14656566.2023.2193668","volume":"24","author":"MW McCarthy","year":"2023","unstructured":"McCarthy, M. W. VV116 as a potential treatment for COVID-19. Expert Opin. Pharmacother. 24, 675\u2013678 (2023).","journal-title":"Expert Opin. Pharmacother."},{"key":"8651_CR42","unstructured":"Merck and Ridgeback Provide Update on EU Marketing Authorization Application for Lagevrio\u2122 (Molnupiravir) (Merck, 2023); https:\/\/www.merck.com\/news\/merck-and-ridgeback-provide-update-on-eu-marketing-authorization-application-for-lagevrio-molnupiravir-2\/."},{"key":"8651_CR43","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","volume":"112","author":"C Marzolini","year":"2022","unstructured":"Marzolini, C. et al. Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (paxlovid) and comedications. Clin. Pharmacol. Ther. 112, 1191\u20131200 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"8651_CR44","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.7326\/M23-2887","volume":"176","author":"MS Cohen","year":"2023","unstructured":"Cohen, M. S. & Brown, E. R. Rebound of COVID-19 with nirmatrelvir-ritonavir antiviral therapy. Ann. Intern. Med. 176, 1672\u20131673 (2023).","journal-title":"Ann. Intern. Med."},{"key":"8651_CR45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 22, 449\u2013475 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"8651_CR46","doi-asserted-by":"crossref","first-page":"1125246","DOI":"10.3389\/fimmu.2023.1125246","volume":"14","author":"Y Yuan","year":"2023","unstructured":"Yuan, Y., Jiao, B., Qu, L., Yang, D. & Liu, R. The development of COVID-19 treatment. Front. Immunol. 14, 1125246 (2023).","journal-title":"Front. Immunol."},{"key":"8651_CR47","unstructured":"Therapeutics and COVID-19: Living Guideline, 13 January 2023 (WHO, 2023)."},{"key":"8651_CR48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601\u2013615 (2021).","journal-title":"Nat. Med."},{"key":"8651_CR49","doi-asserted-by":"publisher","unstructured":"Sedova, M., Jaroszewski, L., Iyer, M. & Godzik, A. Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populations. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.05.27.493798 (2022).","DOI":"10.1101\/2022.05.27.493798"},{"key":"8651_CR50","doi-asserted-by":"publisher","unstructured":"Wang, L. et al. COVID-19 rebound after paxlovid and molnupiravir during January-June 2022. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2022.06.21.22276724 (2022).","DOI":"10.1101\/2022.06.21.22276724"},{"key":"8651_CR51","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/bcp.15089","volume":"88","author":"S Akinbolade","year":"2022","unstructured":"Akinbolade, S. et al. Combination therapies for COVID-19: an overview of the clinical trials landscape. Br. J. Clin. Pharmacol. 88, 1590\u20131597 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"8651_CR52","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1128\/CMR.00017-06","volume":"19","author":"CH Calisher","year":"2006","unstructured":"Calisher, C. H., Childs, J. E., Field, H. E., Holmes, K. V. & Schountz, T. Bats: important reservoir hosts of emerging viruses. Clin. Microbiol. Rev. 19, 531\u2013545 (2006).","journal-title":"Clin. Microbiol. Rev."},{"key":"8651_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"AR Fehr","year":"2015","unstructured":"Fehr, A. R. & Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 1282, 1\u201323 (2015).","journal-title":"Methods Mol. Biol."},{"key":"8651_CR54","doi-asserted-by":"crossref","unstructured":"Hu, Y. et al. Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir. ACS Cent Sci 9, 1658\u20131669 (2023).","DOI":"10.1021\/acscentsci.3c00538"},{"key":"8651_CR55","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","volume":"622","author":"Y Duan","year":"2023","unstructured":"Duan, Y. et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 622, 376\u2013382 (2023).","journal-title":"Nature"},{"key":"8651_CR56","doi-asserted-by":"crossref","DOI":"10.1038\/srep32340","volume":"6","author":"PD Mosier","year":"2016","unstructured":"Mosier, P. D. et al. Broad spectrum anti-influenza agents by inhibiting self-association of matrix protein 1. Sci. Rep. 6, 32340 (2016).","journal-title":"Sci. Rep."},{"key":"8651_CR57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nbt.1638","volume":"28","author":"RY Kao","year":"2010","unstructured":"Kao, R. Y. et al. Identification of influenza A nucleoprotein as an antiviral target. Nat. Biotechnol. 28, 600\u2013605 (2010).","journal-title":"Nat. Biotechnol."},{"key":"8651_CR58","doi-asserted-by":"publisher","unstructured":"Laporte, M. et al. A coronavirus assembly inhibitor that targets the viral membrane protein. Nature https:\/\/doi.org\/10.1038\/s41586-025-08773-x (2025).","DOI":"10.1038\/s41586-025-08773-x"},{"key":"8651_CR59","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"8651_CR60","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","volume":"370","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464\u20131468 (2020).","journal-title":"Science"},{"key":"8651_CR61","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/s41564-023-01476-x","volume":"8","author":"YJ Hou","year":"2023","unstructured":"Hou, Y. J. et al. Host range, transmissibility and antigenicity of a pangolin coronavirus. Nat. Microbiol. 8, 1820\u20131833 (2023).","journal-title":"Nat. Microbiol."},{"key":"8651_CR62","doi-asserted-by":"crossref","first-page":"eadg5567","DOI":"10.1126\/scitranslmed.adg5567","volume":"15","author":"LV Tse","year":"2023","unstructured":"Tse, L. V. et al. A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus. Sci. Transl. Med. 15, eadg5567 (2023).","journal-title":"Sci. Transl. Med."},{"key":"8651_CR63","first-page":"222","volume":"105789","author":"J Doijen","year":"2023","unstructured":"Doijen, J. et al. A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects. Antiviral Res. 105789, 222 (2023).","journal-title":"Antiviral Res."},{"key":"8651_CR64","doi-asserted-by":"crossref","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","volume":"198","author":"L Vangeel","year":"2022","unstructured":"Vangeel, L. et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 198, 105252 (2022).","journal-title":"Antiviral Res."},{"key":"8651_CR65","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jviromet.2012.04.011","volume":"183","author":"D Jochmans","year":"2012","unstructured":"Jochmans, D., Leyssen, P. & Neyts, J. A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE. J. Virol. Methods 183, 176\u2013179 (2012).","journal-title":"J. Virol. Methods"},{"key":"8651_CR66","doi-asserted-by":"crossref","first-page":"eabm3410","DOI":"10.1126\/scitranslmed.abm3410","volume":"14","author":"A Sch\u00e4fer","year":"2022","unstructured":"Sch\u00e4fer, A. et al. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Sci. Transl. Med. 14, eabm3410 (2022).","journal-title":"Sci. Transl. Med."},{"key":"8651_CR67","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TP Sheahan","year":"2020","unstructured":"Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).","journal-title":"Sci. Transl. Med."},{"key":"8651_CR68","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"8651_CR69","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ymeth.2011.07.005","volume":"55","author":"PD Adams","year":"2011","unstructured":"Adams, P. D. et al. The Phenix software for automated determination of macromolecular structures. Methods 55, 94\u2013106 (2011).","journal-title":"Methods"},{"key":"8651_CR70","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/biom12121764","volume":"12","author":"S Rosignoli","year":"2022","unstructured":"Rosignoli, S. & Paiardini, A. Boosting the full potential of PyMOL with structural biology plugins. Biomolecules 12, 1764 (2022).","journal-title":"Biomolecules"},{"key":"8651_CR71","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"8651_CR72","doi-asserted-by":"crossref","first-page":"26955","DOI":"10.1073\/pnas.2014441117","volume":"117","author":"SJF Kaptein","year":"2020","unstructured":"Kaptein, S. J. F. et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2\u2212infected hamsters, whereas hydroxychloroquine lacks activity. Proc. Natl Acad. Sci. USA 117, 26955\u201326965 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8651_CR73","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08651-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08651-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08651-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T20:02:13Z","timestamp":1744574533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08651-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":73,"journal-issue":{"issue":"8058","published-print":{"date-parts":[[2025,4,10]]}},"alternative-id":["8651"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-08651-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3975125\/v1","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.V.L., E.V.D., M.V.G. and C.B. are named as inventors on a pending patent application claiming inhibitors of coronavirus (WO 2024\/008909), which was filed by the Applicant Janssen Pharmaceutica. M.V.L., E.V.D., J.X., S.J., L.G., J.D., M.V.G., R.D.-A., A.D., S. Marsili, S. Miller, C.V.d.E., A.D.R., P.V., K.T., D.P. and C.B. were\/are employees of Janssen Pharmaceutica and may possess stocks of Johnson & Johnson. S. Miller is an employee of Spark Therapeutics and may possess stocks of Roche. N.V.d.B., L.T., V.R. and I.D.P. are employees of Charles River Laboratories, a contract research organization and may possess stocks of Johnson & Johnson. M.S. is an employee of Gilead Sciences and may possess stocks of Gilead Sciences. A.A.L., H.L.M.d.G., E.J.S. and M.J.v.H. received funding from Janssen Pharmaceutica to perform contract research. M.D.T., M.Z. and F.J.M.v.K. received funding from Janssen Pharmaceutica to perform contract research. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}